论文部分内容阅读
在我国,每年新增的胃癌患者中,局部进展期胃癌(LAGC)占大宗。Dn 2根治性手术及其术后辅助化疗已取得了普遍的共识,该治疗策略明显改善了LAGC患者的预后,但是术后复发率仍然较高(50%~80%),致使远期疗效难以进一步提高。围手术期治疗,特别是术前新辅助治疗(NAT)能否提高LAGC疗效,已受到越来越多的关注。NAT主要定义为术前新辅助化疗或放化疗,旨在使肿瘤临床降期,提高根治手术切除率;减灭微小转移灶,并检测自体对化疗药物的敏感性等。然而,对于LAGC患者能否从NAT中生存获益,仍存有争议并缺乏高度共识。本文回顾与分析了LAGC患者围手术期治疗的现状,特别列举了诸多高水平临床研究的结果;同时也初步探讨了围手术期化疗联合分子靶向与免疫治疗的成效。当我们继续实施NAT并期待更多高质量循证医学证据的同时,必须再次强调Rn 0根治性手术才是治愈LAGC患者最重要的手段。n “,”Local advanced gastric cancer (LAGC) accounts for a large proportion of annual newly diagnosed gastric cancer patients in China. There is a general consensus for D2 radical gastrectomy followed by postoperative adjuvant chemotherapy for LAGC patients, and this therapeutic strategy has been confirmed by a series of clinical trials to obviously improve the patients' prognosis; however, the recurrence rate is still high (about 50%-80% in advanced stage), which makes it difficult to further improve the long-term survival. Perioperative therapy, especially whether preoperative neoadjuvant therapy (NAT) can improve the efficacy of patients with LAGC, has been paid more and more attention. NAT is mainly defined as a preoperative chemotherapy or chemoradiotherapy, aiming at increasing curative resection rate by downstaging tumor, eliminating micrometastases, and autologously testing of anti-cancer drug sensitivity etc. However, there are still some controversy whether LAGC patients could gain survival benefit from NAT and also lack of general consensus for this issue. In this paper, the author reviews and analyzes the current situation of perioperative therapies for LAGC patients, especially emphasize the results of neoadjuvant chemotherapy or chemoradiotherapy reported by various high-level clinical studies. The preliminary effect of perioperative chemotherapy combined with molecular targeted or immunotherapy has also aroused great interest and attention. While we continue to carry out NAT and look forward to more new high-level evidence trials on NAT, we must emphasize again that R0 gastrectomy remains the most important therapeutic modality for the patients with LAGC.